AMBER AULAKH: Open Payments
NPI 1124675095 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,359 in 79 payments from 13 companies in 2025. Trend: 2023 $1,172 · 2024 $1,967 · 2025 $1,359
Food & beverage: $1,259Education: $100
| Company | Payments | Amount |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | 10 | $281 |
| Incyte Corporation | 23 | $260 |
| Regeneron Healthcare Solutions, Inc. | 4 | $159 |
| Janssen Biotech, Inc. | 4 | $152 |
| Verrica Pharmaceuticals Inc. | 20 | $143 |
| Novartis Pharmaceuticals Corporation | 3 | $82 |
| ABBVIE INC. | 4 | $61 |
| Galderma Laboratories, L.P. | 2 | $49 |
| UCB, Inc. | 2 | $48 |
| GENZYME CORPORATION | 2 | $43 |
Products named: Zoryve, OPZELURA, DUPIXENT, TREMFYA, YCANTH, COSENTYX, NEMLUVIO, Bimzelx.
Industry payments across CA — which companies pay providers there.
